Content by IONTAS
Potent antibodies shown to retain binding to major COVID-19-causing “South African” variant
| 2 min read
Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline
| 1 min read
The agreement is to generate and optimize antibodies for novel immuno-oncology targets
| 2 min read
IONTAS Limited announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd.
| 1 min read
Funding will be used to further develop IONTAS’ ion-channel targeting KnotBody antibody platform to block pain transmission via Nav1.7
| 2 min read
IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen
| 1 min read
New project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study
| 1 min read
Page 1 of 1 - 7 Total Items
